Log in

Relevant bibliographies by topics / Fenofibric Acid / Journal articles

To see the other types of publications on this topic, follow the link: Fenofibric Acid.

Journal articles on the topic 'Fenofibric Acid'

Author: Grafiati

Published: 3 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Fenofibric Acid.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Hoàng, Việt Dũng, Quang Anh Lương, Hòa Bình Nguyễn та ін. "NGHIÊN CỨU THIẾT LẬP CHUẨN ACID FENOFIBRIC". Tạp chí Y Dược học Cần Thơ, № 83 (25 січня 2025): 60–67. https://doi.org/10.58490/ctump.2025i83.3327.

Full text

Abstract:

Đặt vấn đề: Chuẩn acid fenofibric là yêu cầu bắt buộc trong một số phương pháp phân tích (như HPLC, GC, LC_MS/MS) để kiểm tra chất lượng nguyên liệu và thành phẩm chứa acid fenofibric, do vậy thiết lập chất chuẩn acid fenofibric là yêu cầu cấp thiết ở Việt Nam. Mục tiêu nghiên cứu: Xây dựng tiêu chuẩn cơ sở và thiết lập chuẩn thứ cấp của acid fenofibric được tổng hợp tại Việt Nam. Đối tượng và phương pháp nghiên cứu: Acid fenofibric được tổng hợp bằng cách thủy phân ester fenofibrat trong môi trường base (NaOH) và tinh chế bằng phương pháp thông dụng. Cấu trúc sản phẩm được xác định bằng: IR,

APA, Harvard, Vancouver, ISO, and other styles

2

Suhery, Wira Noviana, Nofriyanti, and Annisa Permatasari. "PENGARUH TEKNIK LIQUISOLID MENGGUNAKAN TRANSCUTOL® HP TERHADAP DISOLUSI ASAM FENOFIBRAT." Jurnal Penelitian Farmasi Indonesia 12, no. 2 (2023): 104–10. http://dx.doi.org/10.51887/jpfi.v12i2.1905.

Full text

Abstract:

Kelarutan merupakan salah satu parameter yang dapat mempengaruhi ketersediaan hayati obat. Obat-obatan dengan kelarutan yang rendah membutuhkan dosis tinggi untuk mencapai konsentrasi oral terapeutik. Asam fenofibrat adalah obat yang memiliki kelarutan dalam air yang rendah dan permeabilitas yang tinggi. Salah satu cara untuk mengatasi masalah kelarutan adalah dengan teknik liquisolid. Penelitian ini bertujuan untuk mengetahui pengaruh teknik liquisolid asam fenofibrat terhadap disolusinya. Formulasi dengan teknik liquisolid dibuat dengan jenis dan jumlah yang bervariasi menggunakan pelarut Tr

APA, Harvard, Vancouver, ISO, and other styles

3

Yang, Lily P. H., and Gillian M. Keating. "Fenofibric Acid." American Journal Cardiovascular Drugs 9, no. 6 (2009): 401–9. http://dx.doi.org/10.2165/11203920-000000000-00000.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Rath, Nigam P., Wahajul Haq, and Ganesaratnam K. Balendiran. "Fenofibric acid." Acta Crystallographica Section C Crystal Structure Communications 61, no. 2 (2005): o81—o84. http://dx.doi.org/10.1107/s0108270104032573.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Anggraini, Deni, Gressy Novita, and Intan Wulandari. "IMPROVED SOLUBILITY NOVEL MULTICOMPONENT CRYSTALS OF FENOFIBRIC ACID-ACETYLSALISYLIC ACID." Medical Sains : Jurnal Ilmiah Kefarmasian 10, no. 1 (2025): 89–98. https://doi.org/10.37874/ms.v10i1.1690.

Full text

Abstract:

Solubility is an important physicochemical property of active pharmaceutical ingredients. Poor water solubility of active pharmaceutical ingredients leads to low bioavailability; therefore, efforts are needed to improve the solubility of active pharmaceutical ingredients. The goal of this study was to prepare and characterize novel multicomponent crystals of fenofibric acid (FA) using acid acetylsalicylic (ACE) as a coformer and to evaluate the solubility enhancement when prepared for multicomponent crystal formation. Solid characterization of the novel multicomponent crystals was performed us

APA, Harvard, Vancouver, ISO, and other styles

6

Dubey, Sunil K., Manoj S. Tomar, Anil Kumar Patni, Arshad Khuroo, Simrit Reyar, and Tausif Monif. "Rapid, Sensitive and Validated Ultra-Performance Liquid Chromatography/Mass Spectrometric Method for the Determination of Fenofibric Acid and its Application to Human Pharmacokinetic Study." E-Journal of Chemistry 7, no. 1 (2010): 25–36. http://dx.doi.org/10.1155/2010/726124.

Full text

Abstract:

The first, rapid and sensitive ultra performance liquid chromatography mass spectrometric method for the determination of fenofibric acid, the active metabolite of fenofibrate, a lipid regulating agent, in human EDTA plasma has been developed and validated using fenofibric d6 acid as internal standard and Waters LC-MS/MS. Negative ions of fenofibric acid and fenofibric d6 acid were detected in multiple reaction-monitoring (MRM) mode. The method was validated over a concentration range of 0.176 μg/mL to 19.837 μg/mL (r ≥ 0.99). It took only 1.5 minute to analyse a sample. Intra- and inter-run p

APA, Harvard, Vancouver, ISO, and other styles

7

Saurav, Alok, Manu Kaushik, and Syed M. Mohiuddin. "Fenofibric acid for hyperlipidemia." Expert Opinion on Pharmacotherapy 13, no. 5 (2012): 717–22. http://dx.doi.org/10.1517/14656566.2012.658774.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Kim, Tae. "Determination of Fenofibric Acid in Rat Plasma and its Application to a Comparative Pharmacokinetic Study of JW322 and Fenofibrate." Drug Research 67, no. 09 (2017): 534–38. http://dx.doi.org/10.1055/s-0043-109243.

Full text

Abstract:

AbstractIn this study, a sensitive and reliable method for the quantitation of fenofibric acid in rat plasma was developed and validated using high performance liquid chromatography (HPLC). The plasma samples were prepared by deproteinization, and sildenafil was used as an internal standard. Chromatographic separation was achieved using a reversed-phase (C18) column. The mobile phase, 0.02 M ammonium acetate buffer:acetonitrile (35:65, v/v), was run at a flow rate of 1.0 mL/min, and the column eluent was monitored using an ultraviolet detector at 280 nm at room temperature. The retention times

APA, Harvard, Vancouver, ISO, and other styles

9

Bala, Vishnu Priya Mukkala *. Gopala Krishna Murthy Talasila and Prameela Rani Avula. "DEVELOPMENT OF FENOFIBRIC ACID DELAYED RELEASE PELLETS: OPTIMIZATION OF PROCESS VARIABLES IN FLUID BED PROCESS." INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES 05, no. 02 (2018): 1207–18. https://doi.org/10.5281/zenodo.1188922.

Full text

Abstract:

The objective of the present study was to optimize the process of Fenofibric acid delayed release (DR) pellets. Wurster (Bottom spray fluid bed coating) process was employed to develop the Fenofibric acid DR pellets. This study assesses the impact of various process variables on drug layering by using statistical interpretation such as ANOVA. A face centered central composite design (CCD) was employed to study the effect of independent variables (product temperature, atomization air pressure, fluidization air volume and spray rate) on dependent variables (Fines, agglomerates, coating efficienc

APA, Harvard, Vancouver, ISO, and other styles

10

SUSHMA, P., and DR A. K. M. PAWAR. "Development of a New Validated Stability Indicating Method for Quantification of Fenofibric acid and Pitavastatin by Ultra Performance Liquid Chromatography." YMER Digital 21, no. 03 (2022): 287–99. http://dx.doi.org/10.37896/ymer21.03/32.

Full text

Abstract:

The main objective of the present work is to develop an efficient, unique, reliable Ultra performance liquid chromatographic method for the simultaneous quantificaiton of Fenofibric acid and Pitavastatin in bulk and Pharmaceutical formulations. The Chromatographic separation of the selected combination of drugs was performed on a Kinetex C8 column (150mm x4.6mm, 2.6 µ) using an isocratic elution with a buffer containing 0.1% formic acid and acetonitrile at a ratio of 80:20 as a mobile phase with a flow rate of 0.5 mL/min at ambient temperature and wavelength at 266nm.The method produced reliab

APA, Harvard, Vancouver, ISO, and other styles

11

Gandhimathi, M., Sneha M. John, and T. K. Ravi. "NOVEL RPHPLC-PDA METHOD FOR SIMULTANEOUS ESTIMATION OF HEPARIN AND ITS CO-ADMINISTERED DRUG (FENOFIBRIC ACID) IN MIXTURE." INDIAN DRUGS 58, no. 01 (2021): 73–75. http://dx.doi.org/10.53879/id.58.01.11856.

Full text

Abstract:

The poly prescription and co-administration of more than two drugs to treat patients for the disease conditions are inexorable. Heparin is and anticoagulant often administered with fenofibric acid in cardiac treatments. A reverse phased high-performance liquid chromatography method based on photo diode array detection has been developed for their simultaneous determination from admixture. They were separated using potassium dihydrogen orthophosphate: acetonitrile (20:80, V/V), on C18 column, at a flow rate of 0.8 mL/min. The retention time of Heparin and fenofibric acid was 3.8 and 13.1 min, r

APA, Harvard, Vancouver, ISO, and other styles

12

Wong, Rina P. M., and Timothy M. E. Davis. "In VitroAntimalarial Activity and Drug Interactions of Fenofibric Acid." Antimicrobial Agents and Chemotherapy 56, no. 6 (2012): 2814–18. http://dx.doi.org/10.1128/aac.05076-11.

Full text

Abstract:

ABSTRACTPlasmodium falciparumhas developed resistance to most available treatments, underscoring the need for novel antimalarial drugs. Fibrates are lipid-modifying agents used to reduce morbidity and mortality associated with cardiovascular disease. They may have antimalarial activity through modulation of P-glycoprotein and ATP-binding cassette subfamily A member (ABC-1)-mediated nutrient transport and/or via a putative peroxisome proliferator-activated receptor alpha-like protein. We therefore examinedin vitroantimalarial activities of fibrates and their interactions with chloroquine and di

APA, Harvard, Vancouver, ISO, and other styles

13

Honda, Akihiro, Shotaro Kamata, Makoto Akahane та ін. "Functional and Structural Insights into Human PPARα/δ/γ Subtype Selectivity of Bezafibrate, Fenofibric Acid, and Pemafibrate". International Journal of Molecular Sciences 23, № 9 (2022): 4726. http://dx.doi.org/10.3390/ijms23094726.

Full text

Abstract:

Among the agonists against three peroxisome proliferator-activated receptor (PPAR) subtypes, those against PPARα (fibrates) and PPARγ (glitazones) are currently used to treat dyslipidemia and type 2 diabetes, respectively, whereas PPARδ agonists are expected to be the next-generation metabolic disease drug. In addition, some dual/pan PPAR agonists are currently being investigated via clinical trials as one of the first curative drugs against nonalcoholic fatty liver disease (NAFLD). Because PPARα/δ/γ share considerable amino acid identity and three-dimensional structures, especially in ligand-

APA, Harvard, Vancouver, ISO, and other styles

14

Honda, Akihiro, Shotaro Kamata, Makoto Akahane та ін. "Functional and Structural Insights into Human PPARα/δ/γ Subtype Selectivity of Bezafibrate, Fenofibric Acid, and Pemafibrate". International Journal of Molecular Sciences 23, № 9 (2022): 4726. http://dx.doi.org/10.3390/ijms23094726.

Full text

Abstract:

Among the agonists against three peroxisome proliferator-activated receptor (PPAR) subtypes, those against PPARα (fibrates) and PPARγ (glitazones) are currently used to treat dyslipidemia and type 2 diabetes, respectively, whereas PPARδ agonists are expected to be the next-generation metabolic disease drug. In addition, some dual/pan PPAR agonists are currently being investigated via clinical trials as one of the first curative drugs against nonalcoholic fatty liver disease (NAFLD). Because PPARα/δ/γ share considerable amino acid identity and three-dimensional structures, especially in ligand-

APA, Harvard, Vancouver, ISO, and other styles

15

Miller, Chad, Steven Schildcrout, Howard Mettee, and Ganesaratnam Balendiran. "Molecular dynamics of fibric acids." European Journal of Chemistry 13, no. 2 (2022): 186–95. http://dx.doi.org/10.5155/eurjchem.13.2.186-195.2275.

Full text

Abstract:

1H- and 13C-NMR chemical shifts were measured for four fibric acids (bezafibrate, clofibric acid, fenofibric acid, and gemfibrozil), which are lipid-lowering drugs. Correlation is found with DFT-computed chemical shifts from the conformational analysis. Equilibrium populations of optimized conformers at 298 K are very different when based on computed Gibbs energies rather than on potential energies. This is due to the significant entropic advantages of extended rather than bent conformational shapes. Abundant conformers with intramolecular hydrogen bonding via five-member rings are computed fo

APA, Harvard, Vancouver, ISO, and other styles

16

Boscá, Francisco, and Miguel A. Miranda. "A Laser Flash Photolysis Study on Fenofibric Acid." Photochemistry and Photobiology 70, no. 6 (1999): 853–57. http://dx.doi.org/10.1111/j.1751-1097.1999.tb08293.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

MECHCATIE, ELIZABETH. "FDA Panel Divided on Fenofibric Acid Labeling Changes." Internal Medicine News 44, no. 10 (2011): 39. http://dx.doi.org/10.1016/s1097-8690(11)70516-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Shihabi, Zak K. "Fenofibrate and fenofibric acid analysis by capillary electrophoresis." ELECTROPHORESIS 25, no. 1011 (2004): 1648–51. http://dx.doi.org/10.1002/elps.200305849.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Biswas, Kaushik, Ajoy Tiwari, Prachi Jadhav, Amit Goel, and G. V. Chanukya. "Rosuvastatin and Fenofibrate Combination in The Treatment of Mixed Hyperlipidemia: A Narrative Review." Journal of Current Medical Research and Opinion 4, no. 03 (2021): 867–77. http://dx.doi.org/10.15520/jcmro.v4i03.405.

Full text

Abstract:

Introduction: Patients with mixed dyslipidemia are presented with high levels of low-density lipid cholesterol (LDL-C), triglycerides (TG), and reduced high-density lipid cholesterol (HDL-C). Though useful in lowering LDL-C, therapy with rosuvastatin is insufficient in optimizing the overall lipid profile, thus putting the patient at risk of residual cardiovascular risk. A combination of statin with other lipid-modifying agents has been used with more efficient lipid control and cardiovascular risk prevention. Of these, fenofibric acid is the most frequently used, along with rosuvastatin.&#x0D

APA, Harvard, Vancouver, ISO, and other styles

20

Takeda, Masaya, Fumio Otsuka, Hiroyuki Otani та ін. "Effects of peroxisome proliferator-activated receptor activation on gonadotropin transcription and cell mitosis induced by bone morphogenetic proteins in mouse gonadotrope LβT2 cells". Journal of Endocrinology 194, № 1 (2007): 87–99. http://dx.doi.org/10.1677/joe-07-0138.

Full text

Abstract:

Involvement of peroxisome proliferator-activated receptor-γ (PPAR-γ ) activation and bone morphogenetic protein (BMP) signaling in regulating cell proliferation and hormonal production of pituitary tumors has been reported, although the underlying mechanism remains poorly understood. Here, we investigated regulatory roles of PPARα and PPARγ in gonadotropin transcription and cell mitosis modulated by pituitary activin/BMP systems using a mouse gonadotropinoma cell line Lβ T2, which expresses activin/BMP receptors, transcription factor Smads, PPARα , and PPARγ . In Lβ T2 cells, BMP signaling sho

APA, Harvard, Vancouver, ISO, and other styles

21

Le, Tran Van-Hoai, Tuyen Ngoc Truong, Thuong Thi-Thuong Le, and Dung Thanh Phan. "Optimization of the synthesis reaction and establishing the reference standard of Fenofibrate impurity C (USP)." MedPharmRes 9, no. 1 (2025): 49–61. https://doi.org/10.32895/ump.mpr.9.1.5.

Full text

Abstract:

1-methylethyl 2-[[2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl propanoyl]oxy]-2-methylpropanoate (or fenofibrate impurity C, United States Pharmacopoeia [USP]) is an impurity in fenofibrate raw material. To date, publications on synthesis of fenofibrate impurity C (ImpC) have reported low yield and purity, so far. The purpose of this study is to optimize the conditions for synthesis of ImpC using Central Composite Design (CCD) approach and standardization of ImpC as reference substance. ImpC was synthesized from the reaction between fenofibric acid and isopropyl 2-bromo-2-methylpropanoate in dimeth

APA, Harvard, Vancouver, ISO, and other styles

22

ABE, Sadahiro, Kaoru ONO, Masayuki MOGI, and Tokishi HAYASHI. "High-Performance Liquid Chromatographic Method for the Determination of Fenofibric Acid and Reduced Fenofibric Acid in Human Blood, Plasma and Urine." YAKUGAKU ZASSHI 118, no. 10 (1998): 447–55. http://dx.doi.org/10.1248/yakushi1947.118.10_447.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Machado-Duque, Manuel E., Andrés Gaviria-Mendoza, and Jorge E. Machado-Alba. "Real-World Effectiveness of Therapy With Rosuvastatin Combined With Fenofibric Acid in a Sample of Colombian Patients With Mixed Dyslipidemia." Journal of Primary Care & Community Health 11 (January 2020): 215013272097773. http://dx.doi.org/10.1177/2150132720977733.

Full text

Abstract:

Background Ischemic heart disease is the leading cause of death in the world and is associated with dyslipidemia, high blood pressure, diabetes mellitus, and other factors. Objective To determine the clinical effectiveness on the lipid profile of the rosuvastatin + fenofibric acid combination in Colombian patients with high cardiovascular risk and mixed dyslipidemia. Methods Longitudinal observational study in a random sample of patients with a diagnosis of mixed dyslipidemia and moderate, high, or very high cardiovascular risk who were treated with rosuvastatin + fenofibric acid. Anthropometr

APA, Harvard, Vancouver, ISO, and other styles

24

Nobilis, M., J. Kvetina, P. Anzenbacher, et al. "Distribution of fenofibric acid in lipoprotein fractions of patients." European Journal of Drug Metabolism and Pharmacokinetics 23, no. 2 (1998): 287–94. http://dx.doi.org/10.1007/bf03189353.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Al-Tannak, Naser F., and Ahmed Hemdan. "Eco-Friendly Separation of Antihyperlipidemic Combination Using UHPLC Particle-Packed and Monolithic Columns by Applying Green Analytical Chemistry Principles." Separations 8, no. 12 (2021): 246. http://dx.doi.org/10.3390/separations8120246.

Full text

Abstract:

Efficient separation of pharmaceuticals and metabolites with the adequate resolution is a key factor in choosing the most suitable chromatographic method. For quality control, the analysis time is a key factor, especially in pharmacokinetic studies. High back pressure is considered as one of the most important factors in chromatography’s flow control, especially in UHPLC. The separation of the anti-hyperlipidemic mixtures was carried out using two columns: a column silica-based particle packed UHPLC and a monolithic column. The systematic suitability of the two columns was compared for the sep

APA, Harvard, Vancouver, ISO, and other styles

26

Bugier, Sarah, Carine Garcia-Hejl, Philippe Vest, Julie Plantamura, Denis Chianea, and Christophe Renard. "A Cross-Reactivity of Fenofibric Acid With MDMA DRI Assay." Military Medicine 181, no. 9 (2016): 1013–15. http://dx.doi.org/10.7205/milmed-d-15-00442.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Quesada, Loreto, Isabel Gomila, Antonia Fe, et al. "Fenofibric Acid Can Cause False-Positive Urine Methylenedioxymethamphetamine Immunoassay Results." Journal of Analytical Toxicology 39, no. 9 (2015): 734–40. http://dx.doi.org/10.1093/jat/bkv074.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Malátková, Petra, Matthildi Kanavi, Milan Nobilis, and Vladimír Wsól. "In vitro metabolism of fenofibric acid by carbonyl reducing enzymes." Chemico-Biological Interactions 258 (October 2016): 153–58. http://dx.doi.org/10.1016/j.cbi.2016.09.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Rosal, Roberto, María S. Gonzalo, Antonio Rodríguez, and Eloy García-Calvo. "Catalytic ozonation of fenofibric acid over alumina-supported manganese oxide." Journal of Hazardous Materials 183, no. 1-3 (2010): 271–78. http://dx.doi.org/10.1016/j.jhazmat.2010.07.021.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Uppalapati, Dedeepya, Nihar R. Das, Rahul P. Gangwal, Mangesh V. Damre, Abhay T. Sangamwar та Shyam S. Sharma. "Neuroprotective Potential of Peroxisome Proliferator Activated Receptor-αAgonist in Cognitive Impairment in Parkinson’s Disease: Behavioral, Biochemical, and PBPK Profile". PPAR Research 2014 (2014): 1–9. http://dx.doi.org/10.1155/2014/753587.

Full text

Abstract:

Parkinson’s disease (PD) is a common neurodegenerative disorder affecting 1% of the population by the age of 65 years and 4-5% of the population by the age of 85 years. PD affects functional capabilities of the patient by producing motor symptoms and nonmotor symptoms. Apart from this, it is also associated with a higher risk of cognitive impairment that may lead to memory loss, confusion, and decreased attention span. In this study, we have investigated the effect of fenofibrate, a PPAR-αagonist in cognitive impairment model in PD. Bilateral intranigral administration of 1-methyl-4-phenyl-1,2

APA, Harvard, Vancouver, ISO, and other styles

31

Kipnes, Mark S., Eli M. Roth, James M. Rhyne, et al. "Year Two Assessment of Fenofibric Acid and Moderate-Dose Statin Combination." Clinical Drug Investigation 30, no. 1 (2010): 51–61. http://dx.doi.org/10.2165/11319800-000000000-00000.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Massin, Pascale, Tunde Peto, Jean-Claude Ansquer, Patrick Aubonnet, and for the MacuFEN Study Investigators. "Effects of Fenofibric Acid on Diabetic Macular Edema: The MacuFen study." Ophthalmic Epidemiology 21, no. 5 (2014): 307–17. http://dx.doi.org/10.3109/09286586.2014.949783.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Vincent-Viry, M., C. Cossy, M. M. Galteau, R. Gueguen, J. Magdalou, and A. Nicolas. "Lack of a genetic polymorphism in the glucuronidation of fenofibric acid." Pharmacogenetics 5, no. 1 (1995): 50–52. http://dx.doi.org/10.1097/00008571-199502000-00006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Ferdinand, Keith C., Michael H. Davidson, Maureen T. Kelly, Carolyn M. Setze, Rick Schiebinger, and Darryl J. Sleep. "Long-Term Efficacy of Rosuvastatin and Fenofibric Acid 20 mg/135 mg in Dyslipidemic Patients Initially Treated with Rosuvastatin and Fenofibric Acid 10 mg/135 mg." Journal of Clinical Lipidology 4, no. 3 (2010): 210–11. http://dx.doi.org/10.1016/j.jacl.2010.03.034.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Suhery, W. N., Y. C. Sumirtapura, J. S. Pamudji, and D. Mudhakir. "SOLID SELF NANO EMULSIFYING DRUG DELIVERY SYSTEM OF FENOFIBRIC ACID: PHYSICOCHEMICAL PROPERTIES AND IN VITRO EVALUATION." RASAYAN Journal of Chemistry 15, no. 03 (2022): 1916–21. http://dx.doi.org/10.31788/rjc.2022.1536705.

Full text

Abstract:

Physicochemical properties and dissolution of Fenofibric acid (FA) solid self-nano emulsifying drug delivery system (solid SNEDDS) were investigated. Kollisolv® MCT 70 (medium-chain triglyceride), Kolliphor® RH 40, and Transcutol® HP as the oil, surfactant, and cosurfactant for SNEDDS formulation. The optimized SNEDDS formulation was solidified into solid SNEDDS using porous carriers (Neusilin® US2 and Aerosil 200), with a ratio of 33% and 50% (w/v) respectively (SS1–SS4). The selected solid SNEDDS formulation of FA (SS1) could increase the dissolution of FA 1.75-fold compared to the pure drug

APA, Harvard, Vancouver, ISO, and other styles

36

Jones, Peter H. "Fenofibric acid plus statin combination therapy for the treatment of mixed dyslipidemia." Clinical Lipidology 4, no. 6 (2009): 699–711. http://dx.doi.org/10.2217/clp.09.71.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Kumar, Ajay, Tausif Monif, Arshad H. Khuroo, Sunil S. Iyer, Abhishek Kumar Singh та Debashis Kar. "Development and validation of a LC-ESI-MS/MS method in human plasma for quantification of fenofibric acid, involving chromatographic resolution of fenofibric acid acyl-β-d-glucuronide". Analytical Methods 2, № 10 (2010): 1584. http://dx.doi.org/10.1039/c0ay00368a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Susan Marie Schima. "Fenofibric Acid: Safety and Efficacy in the Treatment of Dyslipidemia, Hypertriglyceridemia and Hyperlipidemia." Clinical Medicine Reviews in Vascular Health 3 (2011): 99–105. http://dx.doi.org/10.4137/cmrvh.s5041.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Tojcic, Jelena, Marie-Odile Benoit-Biancamano, Michael H. Court, Robert J. Straka, Patrick Caron, and Chantal Guillemette. "In Vitro Glucuronidation of Fenofibric Acid by Human UDP-Glucuronosyltransferases and Liver Microsomes." Drug Metabolism and Disposition 37, no. 11 (2009): 2236–43. http://dx.doi.org/10.1124/dmd.109.029058.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Vayá, Ignacio, Inmaculada Andreu, Vicente T. Monje, M. Consuelo Jiménez, and Miguel A. Miranda. "Mechanistic Studies on the Photoallergy Mediated by Fenofibric Acid: Photoreactivity with Serum Albumins." Chemical Research in Toxicology 29, no. 1 (2015): 40–46. http://dx.doi.org/10.1021/acs.chemrestox.5b00357.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Kim, Chi Hyun, Ravirala Ramu, Jin Hee Ahn, Myung Ae Bae, and Young Sik Cho. "Fenofibrate but not fenofibric acid inhibits 11beta-hydroxysteroid dehydrogenase 1 in C2C12 myotubes." Molecular and Cellular Biochemistry 344, no. 1-2 (2010): 91–98. http://dx.doi.org/10.1007/s11010-010-0532-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Bovardhouppermans, S., A. Ochoa, J. C. Fruchart, and M. M. Zakin. "Fenofibric Acid Modulates the Human Apolipoprotein A-IV Gene Expression in HepG2 Cells." Biochemical and Biophysical Research Communications 198, no. 2 (1994): 764–69. http://dx.doi.org/10.1006/bbrc.1994.1110.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Lee, Hae Won, Woo Youl Kang, Wookjae Jung, et al. "Evaluation of the Pharmacokinetic Drug–Drug Interaction between Micronized Fenofibrate and Pitavastatin in Healthy Volunteers." Pharmaceutics 12, no. 9 (2020): 869. http://dx.doi.org/10.3390/pharmaceutics12090869.

Full text

Abstract:

Dyslipidemia is a major risk factor for development of atherosclerosis and cardiovascular disease (CVD). Effective lipid-lowering therapies has led to CVD risk reduction. This study evaluated the possible pharmacokinetic interactions between fenofibrate, a peroxisome proliferators-activated receptors α agonist, and pitavastatin, a 3-hydoxy-3-methylglutaryl-coenzyme A reductase inhibitor, in healthy Korean subjects. The study design was an open-label, randomized, multiple-dose, three-period, and six-sequence crossover study with a 10-day washout in 24 healthy volunteers. It had three treatments

APA, Harvard, Vancouver, ISO, and other styles

44

Brautbar, Ariel, Maja Barbalic, Fengju Chen, et al. "RareAPOA5promoter variants associated with paradoxical HDL cholesterol decrease in response to fenofibric acid therapy." Journal of Lipid Research 54, no. 7 (2013): 1980–87. http://dx.doi.org/10.1194/jlr.m034132.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

ANGGRAINI, Deni, and Erizal ZAINI. "Multicomponent crystals of fenofibric acid-L-proline with enhanced dissolution rate and antihyperlipidemic activity." Journal of Research in Pharmacy 28(4), no. 28(4) (2024): 974–81. http://dx.doi.org/10.29228/jrp.780.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Zhu, Tong, Jean-Claude Ansquer, Maureen T. Kelly, Darryl J. Sleep, and Rajendra S. Pradhan. "Comparison of the Gastrointestinal Absorption and Bioavailability of Fenofibrate and Fenofibric Acid in Humans." Journal of Clinical Pharmacology 50, no. 8 (2010): 914–21. http://dx.doi.org/10.1177/0091270009354995.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Guo, Chaorui, Siqi Xue, Xiufen Zheng, et al. "The effect of fenofibric acid on the pharmacokinetics and pharmacodynamics of warfarin in rats." Xenobiotica 48, no. 4 (2017): 400–406. http://dx.doi.org/10.1080/00498254.2017.1306760.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Jones, Peter H., Harold E. Bays, Michael H. Davidson, et al. "Evaluation of a New Formulation of Fenofibric Acid, ABT-335, Co-Administered with Statins." Clinical Drug Investigation 28, no. 10 (2008): 625–34. http://dx.doi.org/10.2165/00044011-200828100-00003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Arafat, Tawfiq, Basil Arafat, Ahmad Abu Awwad, and Oliver J. Schmitz. "Determination of Fenofibric Acid in Human Plasma by LC–MS/MS and LC–UV." Chromatographia 79, no. 11-12 (2016): 685–92. http://dx.doi.org/10.1007/s10337-016-3080-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Cosa, Gonzalo. "Photodegradation and photosensitization in pharmaceutical products: Assessing drug phototoxicity." Pure and Applied Chemistry 76, no. 2 (2004): 263–75. http://dx.doi.org/10.1351/pac200476020263.

Full text

Abstract:

Toxic reactants are a common result of the interaction of sunlight with pharmaceutical agents transported in the blood system or applied topically. Over the past decade there has been a considerable amount of research toward understanding both the unimolecular deactivation pathway of photoexcited pharmaceutical products and their photosensitizing capability in the presence of biological substrates. This work summarizes recent developments in the study of the photodegradation mechanism of ketoprofen, fenofibric acid, and tiaprofenic acid. An analysis of excited-state electronic energy levels, t

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!